CT
CTXR.US Citius Pharmaceuticals Inc
- Market cap
- USD 13.8M
- P/E
- -
- P/B
- 0.21x
- ROE
- -76.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is CTXR.US undervalued?
Graham numberThe Graham number of Citius Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Citius Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Citius Pharmaceuticals Inc yet.
Citius Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammator…
Full company profileCitius Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Citius Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.47M |
| Gross Profit | -1.34K | -2.63K | -1.75K | -893.00 | -152K | -165K | -180K | -194K | -210K | -214K | 1.97M |
| Operating Income | -7.45M | -9.99M | -13.8M | -15.6M | -17.7M | -23.5M | -33.3M | -36.7M | -42.0M | -38.5M | -70.6M |
| EBITDA | -7.45M | -9.98M | -13.8M | -15.5M | -17.6M | -23.4M | -33.1M | -36.5M | -38.6M | -38.2M | -65.2M |
| Net Income | -8.30M | -10.4M | -12.5M | -15.6M | -17.5M | -23.1M | -33.6M | -32.5M | -39.1M | -37.4M | -51.1M |
| EPS | -34 | -28 | -18 | -12 | -11 | -5.31 | -5.76 | -5.38 | -3.38 | -3.38 | -1.95 |
| Balance Sheet | |||||||||||
| Total Assets | 22.0M | 24.4M | 31.1M | 29.0M | 43.8M | 142M | 114M | 104M | 117M | 131M | 142M |
| Total Liabilities | 5.18M | 2.47M | 3.18M | 4.61M | 10.1M | 9.65M | 10.6M | 12.2M | 42.5M | 53.4M | 66.3M |
| Shareholders' Equity | 16.8M | 21.9M | 27.9M | 24.4M | 33.7M | 132M | 103M | 90.8M | 70.1M | 67.6M | 66.6M |
| Cash & Short-term Investments | 294K | 3.20M | 9.18M | 7.89M | 13.9M | 70.1M | 41.7M | 26.5M | 3.25M | 4.25M | 17.0M |
| Total Debt | 673K | 173K | 173K | 173K | 1.35M | 855K | 678K | 481K | 263K | 1.81M | 7.18M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.90M | -7.97M | -11.3M | -12.4M | -16.9M | -24.3M | -28.4M | -29.1M | -28.2M | -26.6M | -30.6M |
| Capital Expenditure | 2.13K | 2.13K | 1.83K | 1.83K | 1.83K | 40.0M | 0.00 | 2.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -5.90M | -7.97M | -11.3M | -12.4M | -16.9M | -64.3M | -28.4M | -29.1M | -28.2M | -26.6M | -30.6M |
| Ratios | |||||||||||
| ROE | -49.5% | -47.3% | -45.0% | -63.9% | -52.1% | -17.4% | -32.7% | -35.8% | -55.9% | -55.4% | -76.7% |
| ROA | -37.8% | -42.5% | -40.4% | -53.7% | -40.1% | -16.2% | -29.5% | -31.4% | -33.6% | -28.6% | -35.9% |
| Net Profit Margin | - | - | - | - | - | - | - | - | - | - | -539.2% |
| Debt to Equity | 0.04x | 0.01x | 0.01x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.03x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Citius Pharmaceuticals Inc dividends
Citius Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Nov 26, 2024.
Who owns Citius Pharmaceuticals Inc
- Insiders 1.80%
- Institutions 4.74%
- Public & others 93.47%
- Shares outstanding 27.5M
- Free float 27.0M
Top funds holding CTXR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 165K | 0.60% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 26.4K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 15.3K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding CTXR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 216K | 0.79% | -12.44% | Jun 2026 |
| Vanguard Capital Management, LLC | 197K | 0.72% | +17.66% | Jun 2026 |
| Miller Financial Services LLC | 130K | 0.47% | +828.57% | Jun 2026 |
| Citadel Advisors Llc | 125K | 0.46% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 123K | 0.45% | +445.38% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 77.8K | 0.28% | 0.00% | Jun 2026 |
| BlackRock Inc | 69.9K | 0.25% | 0.00% | Jun 2026 |
| Northern Trust Corp | 62.7K | 0.23% | +42.68% | Jun 2026 |
| XTX Topco Ltd | 59.2K | 0.22% | +177.99% | Jun 2026 |
| Asset Advisory Group, INC. | 59.0K | 0.22% | 0.00% | Sep 2026 |
| BostonPremier Wealth LLC | 28.0K | 0.10% | 0.00% | Jun 2026 |
| UBS Group AG | 26.3K | 0.10% | -52.14% | Jun 2026 |
| LPL Financial Corp | 25.4K | 0.09% | +1.60% | Jun 2026 |
| State Street Corp | 23.3K | 0.08% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 20.8K | 0.08% | 0.00% | Jun 2026 |
| Arkadios Wealth Advisors | 20.0K | 0.07% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 17.5K | 0.06% | +33.16% | Jun 2026 |
| Sanctuary Advisors, LLC | 11.8K | 0.04% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 11.8K | 0.04% | -67.98% | Jun 2026 |
| R Squared Ltd | 11.0K | 0.04% | 0.00% | Jun 2026 |
Citius Pharmaceuticals Inc company profile
- Company name
- Citius Pharmaceuticals Inc
- Ticker
- CTXR.US
- Exchange
- USA Stocks
- Listed since
- Jul 6, 2017
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 23
- Fiscal year end
- September
- Address
- 11 Commerce Drive, Cranford, NJ, United States, 07016
- Phone
- 908 967 6677
- Website
- citiuspharma.com
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals Inc management
10- Mr. Leonard L. MazurCo-Founder, CEO, Chairman & Secretary · born 1945
- Mr. Myron Z. HolubiakCo-Founder & Executive Vice Chairman · born 1947
- Dr. Myron S. Czuczman M.D.Executive VP & Chief Medical Officer · born 1960
- Mr. Jaime BartushakChief Business Officer & CFO · born 1968
- Mr. Gary F. TalaricoExecutive Vice President of Operations · born 1955
- Ms. Ilanit AllenVice President of Investor Relations & Corporate Communications
- Dr. Alan Lader Ph.D.Senior VP and Head of Clinical Operations & Quality Assurance
- Mr. Dhananjay G. WadekarSenior Vice President of Business Strategy · born 1954
- Mr. Kelly Creighton Ph.D.Executive Vice President of Chemistry, Manufacturing & Controls
- Mr. Nikolas BurlewExecutive Vice President of Quality Assurance